FHTX
Foghorn Therapeutics Inc

589
Loading...
Loading...
News
all
press releases
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·6d ago
News Placeholder
More News
News Placeholder
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies IQVIA and Flagship Pioneering Announce Strategic Collaboration to...
PR Newswire·10d ago
News Placeholder
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·12d ago
News Placeholder
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·30d ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +9.68% and -0.85%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks·4mo ago
News Placeholder
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago

Latest FHTX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.